GRTX vs. ADXN, AEZS, ATHE, CMMB, GHSI, GRAY, MTEM, ERNA, BFRI, and NCNA
Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Addex Therapeutics (ADXN), Aeterna Zentaris (AEZS), Alterity Therapeutics (ATHE), Chemomab Therapeutics (CMMB), Guardion Health Sciences (GHSI), Graybug Vision (GRAY), Molecular Templates (MTEM), Eterna Therapeutics (ERNA), Biofrontera (BFRI), and NuCana (NCNA). These companies are all part of the "pharmaceutical preparations" industry.
Addex Therapeutics (NASDAQ:ADXN) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.
Addex Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
In the previous week, Addex Therapeutics and Addex Therapeutics both had 3 articles in the media. Galera Therapeutics' average media sentiment score of 1.03 beat Addex Therapeutics' score of 0.97 indicating that Addex Therapeutics is being referred to more favorably in the media.
Galera Therapeutics has a net margin of 0.00% compared to Galera Therapeutics' net margin of -644.66%. Addex Therapeutics' return on equity of 0.00% beat Galera Therapeutics' return on equity.
16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 6.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Addex Therapeutics has higher revenue and earnings than Galera Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Galera Therapeutics received 38 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 54.35% of users gave Galera Therapeutics an outperform vote while only 46.15% of users gave Addex Therapeutics an outperform vote.
Summary
Galera Therapeutics beats Addex Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Galera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galera Therapeutics Competitors List
Related Companies and Tools
